Good news in the fight against cancer! This Tuesday, Moderna and Merck confirmed that Phase 2b combining a drug from the Merck lab with Moderna’s messenger RNA system into a vaccine would significantly reduce skin cancer, particularly melanoma. But be patient: Phase 3 trials and more studies are still needed. The explanation, in the note of the day.
